Category: Technology | Published: 2026-07-28
For most of the people living with geographic atrophy, the question has never been whether vision loss could be slowed. It has been whether lost sight could ever come back. For decades, the honest answer from medicine was no.
That answer has now changed. A retinal implant called PRIMA, developed by US company Science Corp, has received regulatory approval across Europe and has become the first treatment shown in clinical trials to restore functional central vision to people with this form of age-related vision loss. The first commercial implants are beginning in Germany, with clinical sites activating across Europe.
This is not a marginal improvement. It is a category shift in what medicine can offer people who have lost the ability to read, recognise faces, or see clearly in the centre of their visual field.
Who Vision Loss From AMD Affects
Age-related macular degeneration is one of the leading causes of vision loss in older adults worldwide. The geographic atrophy form, sometimes called dry AMD, affects more than five million people globally and involves the gradual destruction of the photoreceptor cells at the centre of the retina.
These cells, called the macula, handle central vision: the sharp, detailed sight used for reading, driving, recognising faces, and most of the tasks that make independent daily life possible. As geographic atrophy progresses, the macula deteriorates and central vision loss becomes increasingly severe.
Until now, treatment options have been largely focused on slowing the progression of the disease rather than reversing it. There has been no approved way to restore the central vision that has already been lost. PRIMA is the first treatment to change that.
How the Implant Works
The PRIMA system takes a fundamentally different approach to the problem of vision loss from AMD. Rather than trying to repair or regenerate the damaged photoreceptor cells, which is enormously difficult and has not yet been achieved at clinical scale, it bypasses them entirely.
The system has two components working together. The first is a tiny, ultra-thin implant placed beneath the damaged section of the retina in a surgical procedure. The implant itself is photovoltaic, meaning it converts light into electrical signals. The second component is a pair of specialised glasses with a forward-facing camera that captures what the wearer is looking at, and an eye-facing projector that beams near-infrared light directly onto the implant.
When the near-infrared light hits the implant, it generates the electrical signals that the damaged photoreceptors would normally have produced. Those signals then travel through the remaining healthy retinal cells and along the optic nerve to the brain's visual cortex, where they are processed as sight.
The glasses also include a zoom function designed to enlarge letters and fine detail, which makes practical tasks like reading significantly easier. The entire system is wireless, with no cables or external power connections required during normal use.
What makes this approach particularly elegant is that it does not require the brain to learn an entirely new way of processing information. It uses the visual pathways that are already in place, simply restoring the signal at the point where the disease has interrupted it.
What the Clinical Trial Results Showed
The commercial launch follows the publication of clinical trial results in the New England Journal of Medicine, one of the most rigorous peer-reviewed medical journals in the world.
The trial followed 38 patients across 17 clinical centres in five countries. The headline result was an average improvement of 25.5 letters on the standard eye test chart used to measure visual acuity, equivalent to recovering more than five additional lines of vision. That is a substantial and measurable improvement in central visual function.
The figure that perhaps matters most in everyday terms is this: 84 per cent of participants regained the ability to read letters, numbers, and words. For people whose vision loss had taken away the ability to read a book, a letter, a prescription label, or a price tag, regaining that function represents a significant restoration of independence.
The trial also found that the implant was placed beneath the damaged retinal area without causing a decline in the patients' existing natural vision. People did not have to sacrifice the peripheral vision or residual sight they already had in order to benefit from the implant.
One important clarification: PRIMA is not a cure for age-related macular degeneration. It does not halt or reverse the underlying disease process. The photoreceptors that have been lost do not regenerate. What PRIMA does is restore useful central vision by compensating for what the damaged photoreceptors can no longer do, using technology rather than biology.
Why This Is Bigger Than One Eye Condition
PRIMA is primarily an ophthalmology story, but its significance extends considerably further.
The implant works by converting sensory information into electrical signals that communicate directly with surviving neurons, bypassing the damaged cells in between. That is, in precise technical terms, a brain-computer interface. Science Corp describes PRIMA as the first BCI device to receive CE marking for the restoration of detailed form vision.
Brain-computer interfaces have attracted enormous public attention in recent years, largely through companies like Neuralink, which has focused on restoring movement and communication in people with paralysis. The ambitions are significant, but the clinical results to date have been limited in scale.
PRIMA demonstrates that a focused neural implant, designed to address a specific and well-defined form of sensory loss, can achieve regulatory approval, demonstrate meaningful clinical results across a proper multi-centre trial, and reach commercial launch before many of the higher-profile neurotechnology projects have completed their early-phase trials.
That pattern matters. The more likely path for brain-computer interface technology reaching patients is not through dramatic, broad-capability implants arriving all at once, but through focused medical devices that solve specific problems well and accumulate the clinical evidence needed to gain regulatory trust. PRIMA is an example of that path working.
The same underlying principles that allow PRIMA to bypass damaged photoreceptors and stimulate surviving retinal neurons could, in different configurations, address other forms of sensory loss and neurological impairment. The commercial launch of PRIMA accelerates the credibility of that entire class of technology.
Europe First
The decision to launch commercially in Europe before the United States is also worth noting. CE marking under the EU Medical Device Regulation has enabled Science Corp to make PRIMA available across 30 European countries while regulatory discussions with the US Food and Drug Administration continue.
PRIMA already holds FDA Breakthrough Device designation and Humanitarian Use Device designation, both of which are intended to accelerate access for treatments addressing serious unmet medical needs. But the commercial rollout is happening in Europe first, and the first patients receiving the implant outside clinical trials are European.
For a technology that many assumed would originate and commercialise in the United States, this is a meaningful marker of where advanced medical device regulation in Europe currently stands.
What This Signals for Technology and Business
For businesses and technology leaders, the PRIMA story illustrates something worth understanding about where medical technology is heading.
Neural implants, sophisticated sensor technology, real-time signal processing, and AI-assisted interpretation of biological data are converging into practical clinical tools. The vision loss application is the first commercial example of this convergence reaching patients at scale, but it is not likely to be the last.
Opportunities are developing across the supply chain: medical device manufacturing, surgical training, specialist software development, AI-assisted diagnostic tools, and the healthcare services needed to support patients through implantation and ongoing use. Companies positioned in any of these areas will find the growing adoption of neurotechnology opening new markets over the coming decade.
For those thinking about how emerging technology relates to their own business strategy, these developments are a useful reminder that some of the most significant technology shifts arrive first through highly specific, well-evidenced medical applications before expanding into broader use.
If you want to understand how emerging technologies like AI are reshaping the business landscape and what that means for your organisation, our AI Consultancy page is a good place to start that conversation.